RxSight (NASDAQ:RXST), a maker of light-adjustable intraocular lenses, fell ~28% in the premarket on Thursday after the company slashed its full-year guidance and announced lower-than-expected ...

Piper Sandler initiated coverage of RxSight (RXST) with a Neutral rating and $18 price target The firm likes the company’s novel light adjustable lens technology and that it plays in the ...

RxSight sees Q1 revenue up 28% YoY to $37.9M, but misses consensus of $40.14M. FY25 outlook lowered with revenue forecast cut to $160M-$175M, below consensus of $188.9M. Feel unsure about the ...

Investing.com -- JP Morgan downgraded RxSight to Underweight, citing market, economic, and competitive headwinds that have led to a weaker-than-expected first-quarter performance and a downward ...

BofA lowered the firm’s price target on RxSight (RXST) to $36 from $60 and keeps a Buy rating on the shares. Shares are down 61% since hitting all-time highs in June 2024 as the stock re-rated ...

9 analysts have expressed a variety of opinions on RxSight (NASDAQ:RXST) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick ...